Charles Schwab
BLFS icon

Charles Schwab’s BioLife Solutions BLFS Stock Holding History

Charles Schwab’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.4M Sell
402,896
-589
-0.1% -$13.8K ﹤0.01% 2099
2026
Q1 		$7.7M Buy
403,485
+23,744
+6% +$525K ﹤0.01% 2218
2025
Q4 		$9.18M Buy
379,741
+10,206
+3% +$267K ﹤0.01% 2181
2025
Q3 		$9.43M Buy
369,535
+22,553
+6% +$535K ﹤0.01% 2148
2025
Q2 		$7.47M Buy
346,982
+6,156
+2% +$139K ﹤0.01% 2150
2025
Q1 		$7.78M Sell
340,826
-5,595
-2% -$147K ﹤0.01% 2067
2024
Q4 		$8.99M Buy
346,421
+26,462
+8% +$658K ﹤0.01% 2066
2024
Q3 		$8.01M Buy
319,959
+9,750
+3% +$230K ﹤0.01% 2140
2024
Q2 		$6.65M Buy
310,209
+5,939
+2% +$115K ﹤0.01% 2222
2024
Q1 		$5.64M Buy
304,270
+19,146
+7% +$335K ﹤0.01% 2239
2023
Q4 		$4.63M Buy
285,124
+3,126
+1% +$39.9K ﹤0.01% 2343
2023
Q3 		$3.89M Buy
281,998
+16,754
+6% +$264K ﹤0.01% 2363
2023
Q2 		$5.86M Buy
265,244
+7,389
+3% +$156K ﹤0.01% 2175
2023
Q1 		$5.61M Buy
257,855
+3,889
+2% +$87.5K ﹤0.01% 2150
2022
Q4 		$4.62M Buy
253,966
+5,191
+2% +$107K ﹤0.01% 2252
2022
Q3 		$5.66M Buy
248,775
+23,078
+10% +$494K ﹤0.01% 2151
2022
Q2 		$3.12M Buy
225,697
+53,425
+31% +$784K ﹤0.01% 2395
2022
Q1 		$3.92M Buy
172,272
+6,628
+4% +$174K ﹤0.01% 2387
2021
Q4 		$6.17M Sell
165,644
-27,429
-14% -$1.18M ﹤0.01% 2245
2021
Q3 		$8.17M Sell
193,073
-10,105
-5% -$487K ﹤0.01% 2129
2021
Q2 		$9.04M Buy
203,178
+54,000
+36% +$1.9M ﹤0.01% 2057
2021
Q1 		$5.37M Buy
149,178
+5,441
+4% +$215K ﹤0.01% 2266
2020
Q4 		$5.73M Buy
143,737
+5,260
+4% +$179K ﹤0.01% 2149
2020
Q3 		$4.01M Buy
138,477
+116,108
+519% +$2.51M ﹤0.01% 2185
2020
Q2 		$366K Buy
22,369
+3,971
+22% +$54.7K ﹤0.01% 2958
2020
Q1 		$175K Hold
18,398
– – ﹤0.01% 3034
2019
Q4 		$298K Buy
18,398
+1,402
+8% +$22.8K ﹤0.01% 2973
2019
Q3 		$283K Buy
16,996
+307
+2% +$5.76K ﹤0.01% 2981
2019
Q2 		$283K Buy
+16,689
New +$291K ﹤0.01% 3035

Other funds holding BLFS

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Charles Schwab's BLFS Position: Q2 2026 in Review

Charles Schwab reduced its BioLife Solutions (BLFS) stake by 0.15% in Q2 2026, selling an estimated $13.8K and leaving 402,896 shares worth $11.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2099.

Charles Schwab first reported a position in BLFS in Q2 2019 and has held it in 29 quarters since. 216 funds tracked by Wall St. Rank hold BLFS as of Q2 2026.

  • Charles Schwab held 402,896 shares of BioLife Solutions worth $11.4M as of Q2 2026.
  • Charles Schwab sold 589 BioLife Solutions shares in Q2 2026, an estimated $13.8K.
  • BioLife Solutions made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2099 holding.
  • Charles Schwab first reported a position in BioLife Solutions in Q2 2019 and has held it in 29 quarters since.
  • 216 funds tracked by Wall St. Rank held BioLife Solutions as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.